| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/10-1/50 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | F56; DLC1; DLC-1; CFAP81 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human DLEC1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于DLEC1抗体的3篇参考文献的简要概括(注：以下内容基于领域内典型研究方向构造的示例，具体文献需根据实际数据库查询确认)：
---
1. **文献名称**：*DLEC1作为肿瘤抑制因子在非小细胞肺癌中的表达及临床意义*
**作者**：Zhang Y, et al.
**摘要**：本研究通过免疫组化(使用DLEC1特异性抗体)发现，DLEC1蛋白在非小细胞肺癌组织中显著低表达，且与患者淋巴结转移和生存期缩短相关，提示其作为肿瘤抑制因子的潜在作用。
2. **文献名称**：*肝癌中DLEC1基因甲基化介导的表观遗传沉默及其功能研究*
**作者**：Wang L, et al.
**摘要**：利用Western blot和免疫荧光(基于DLEC1抗体)分析肝癌样本，发现DLEC1启动子区高甲基化导致其蛋白表达沉默，恢复表达可抑制肝癌细胞增殖，表明其表观遗传调控机制。
3. **文献名称**：*DLEC1抗体在结直肠癌组织芯片中的表达验证与应用*
**作者**：Chen R, et al.
**摘要**：研究开发并验证了一种高特异性DLEC1多克隆抗体，通过组织芯片分析证实DLEC1在结直肠癌中的表达缺失与肿瘤分期和转移显著相关，为预后评估提供工具。
---
如需具体文献，建议通过PubMed或Google Scholar以“DLEC1 antibody”、“DLEC1 expression cancer”等关键词检索，并筛选涉及抗体应用的基础或临床研究。
The DLEC1 (Deleted in Lung and Esophageal Cancer 1) antibody is a tool used to detect the DLEC1 protein, a putative tumor suppressor implicated in multiple cancers. The DLEC1 gene, located on chromosome 3p22–21.3. is frequently epigenetically silenced via promoter hypermethylation or deleted in malignancies such as lung, esophageal, ovarian, and hepatocellular carcinomas. DLEC1 is thought to regulate cell proliferation, apoptosis, and metastasis suppression, though its precise molecular mechanisms remain under investigation.
DLEC1 antibodies are primarily utilized in research to study its expression patterns and functional roles in carcinogenesis. Reduced or absent DLEC1 protein levels, detected via immunohistochemistry (IHC), Western blotting, or immunofluorescence, correlate with tumor progression and poor prognosis in certain cancers. These antibodies also aid in exploring DLEC1's interaction with signaling pathways, such as Wnt/β-catenin or PI3K/AKT, to uncover therapeutic targets.
Despite its potential as a biomarker, DLEC1's clinical utility is limited by incomplete understanding of its biological functions and heterogeneity across cancer types. Ongoing research focuses on validating its diagnostic, prognostic, and therapeutic relevance, emphasizing the need for high-specificity antibodies to ensure accurate detection in experimental and potential clinical settings.
×
